Skip to main content
TG THERAPEUTICS, INC. logo

TG THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · TGTX ISIN · US88322Q1085 LEI · 529900X21UKABN9NJ529 US Manufacturing
Open in API
Filings indexed 1,012 across all filing types
Latest filing 2016-04-29 Proxy Solicitation & In…
Country US United States of America
Listing US TGTX

About TG THERAPEUTICS, INC.

https://www.tgtherapeutics.com/

TG Therapeutics, Inc. is a fully integrated, commercial-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. The company's primary area of focus is autoimmune diseases, particularly multiple sclerosis (MS). Its lead commercial product is BRIUMVI® (ublituximab), an approved therapy for adults with relapsing forms of MS. TG Therapeutics also develops a pipeline of potential therapies for B-cell malignancies and other autoimmune conditions, including investigational CAR-T cell therapies.

Recent filings

Filing Released Lang Actions
DEF 14A
Proxy Solicitation & Information Statement
2016-04-29 English
OWNERSHIP DOCUMENT
Director's Dealing
2016-04-20 English
FORM S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 registration statement filed with the SEC, which is used to register securities to be offered under employee benefit plans. It includes details about the securities to be registered, the registration fee, incorporation by reference of other SEC filings, indemnification provisions, and undertakings related to the registration. It is not a financial report, earnings release, or management discussion, but a regulatory filing related to securities registration under the Securities Act of 1933. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length and content confirm it is not a brief announcement or a report publication announcement but a full regulatory filing.
2016-03-15 English
10-K
Annual Report FY 2015
2016-03-15 English
CURRENT REPORT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events. The text specifically mentions that the company issued a press release announcing results of operations for the fourth quarter and year ended December 31, 2015, and that an investor conference call would be held. The document itself does not contain detailed financial statements or substantive financial data but rather announces the release of such information and the upcoming call. The document length is 2707 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this filing is best classified as a Regulatory Filing (RNS) because it is a current report announcing financial results and an event but does not contain the full financial report or detailed data itself.
2016-03-07 English
Major Shareholding Notification 2016
Major Shareholding Notification
2016-02-16 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.